B. Braun New Ventures’ Post

Successful deals start with trust. At LSI USA ‘23, Chris Eso having led multiple key deals at Medtronic shared two important components in the recipe for a successful acquisition: Identifying a strong strategic fit, and meeting financial expectations for both shareholders and investors. Having great technology in a great market is table stakes. In a landscape where you’re often vying for a deal against others in a competitive market, there needs to be clear alignment on fit and financials to tip the scales in your favor. As Chris says, nothing is ever completely “one sided” — you have to “feel a little pain and give a little pain” which is made much more palatable when you have that clear alignment on fit and financials. Learn more by watching the full panel, The Anatomy of a Medtech Deal, here: https://lnkd.in/e_qmNW8b

It's a solid base for a spin off that matured under 3M. Here's our starting metrics

In her latest interview with Cheddar on the floor of the NYSE, Align CEO Dena Jalbert discusses the resurgence of vertical integration in M&A, particularly in tech and healthcare sectors. Dena emphasizes the abundance of cash seeking investment opportunities and predicts strong M&A activity in tech, AI, industrials, pharmaceuticals, medical devices, and biotech, with private investment remaining robust in the second half of the year. Watch the full interview to hear her insights about what to expect in M&A for the rest of 2024. #MandA #Business #Finance #Cheddar #NYSE #MergersAndAcquisitions

Erin Clark, Head of Investor Relations at EyePoint Pharmaceuticals has been appointed to the speaking faculty for the upcoming M&A Conference at Cornell Tech New York City, which is hosted by the Transaction Advisors Institute. A few of the questions she will be addressing: - When should M&A teams begin conditioning stakeholders around a transaction? - How are the most effective deal teams navigating a range of polarizing issues, engaging with policy influencers, and anticipating protectionist dynamics? - Are there clever ways to structure deals to absorb regulatory uncertainty, address labor impacts, aligning with institutional investors, and head-off activist sentiment? - What are the current best practices for M&A specific multidisciplinary communications? We're going to talk about what's new, what's different, and what's clever so we can help our members improve their M&A process and the performance of future acquisitions. 🔗See the full agenda: https://hubs.li/Q02N_Xrw0 #mergersacquisitionsdivestitures #mergersandacquisitions #corporatedevelopment

🫨🫨🫨🫨 But also, how do we think this will affect the relationship Hanger has with other manufacturers and what happens to TASKA™ Prosthetics who uses Fillauer as a distributor…? I definitely think there will be some preferences formed for the product used but, we all know the reality is that no one product will fit every need. It’s almost like the opposite of what some manufacturers are doing in purchasing clinics… And, will this actually go through?!? I would love your thoughts as my brain is spinning. #hanger #fillauer #oandp #acquisition

"In the life sciences, M&A is a sign of health. If we see a slowdown in M&A, we see a slowdown in bringing new drugs to patients." During a recent webinar with PULSE (Partnership for the US Life Science Ecosystem), our executive director John Stanford discussed the vital role of mergers and acquisitions in the life sciences. Watch the webinar here: https://lnkd.in/gXEbGQX6

𝐅𝐫𝐨𝐦 𝐊𝐧𝐨𝐜𝐤𝐨𝐮𝐭 𝐭𝐨 𝐂𝐨𝐦𝐞𝐛𝐚𝐜𝐤: 𝐇𝐨𝐰 Boston Scientific 𝐏𝐮𝐥𝐥𝐞𝐝 𝐚 𝐑𝐨𝐜𝐤𝐲!   𝐓𝐡𝐞 𝐊𝐧𝐨𝐜𝐤𝐨𝐮𝐭 𝐏𝐮𝐧𝐜𝐡   In Jan 2006, Boston Scientific won the bidding war against Johnson & Johnson (J&J) and acquired Guidant for $27B, the largest #medtech #acquisition at the time. However, after the acquisition, everything that could go wrong did go wrong. Guidant, already involved in lawsuits and government investigations over issues with its heart devices, continued to encounter problems and massive #recalls. Over the following years, Boston Scientific worked to resolve these issues, took substantial write-downs, and reported significant losses, leading to a sharp decline in its market cap. J&J also filed a #lawsuit seeking $7B in damages, accusing Guidant (now Boston Scientific) of breaking the original deal. At trial, Boston Scientific argued that J&J should not get any damages because it was better off losing the bidding war, admitting the acquisition was a bad deal. By 2010, many believed the company would never recover. By 2012, a company that once had a $34B valuation and made a $27B acquisition was worth only $8B, less than one-third of what it paid for Guidant.   𝐓𝐡𝐞 𝐂𝐨𝐦𝐞𝐛𝐚𝐜𝐤   Since 2012, Boston Scientific has undergone a significant transformation. Under new leadership, the company focused on organic #growth and market expansion by launching new products. It also shifted its acquisition strategy to smaller, tuck-in type acquisitions, typically valued at less than a billion dollars. Additionally, it made substantial improvements to its #culture, #values, and reputation, which ultimately enhanced its financial performance. Finally, in 2015, Boston Scientific paid $0.6B to J&J to settle its long-running lawsuit. Today, the company is firing on all cylinders. With a valuation exceeding $120B, Boston Scientific stands as one of the most valuable medical device companies, proving many skeptics wrong.   As 𝐑𝐨𝐜𝐤𝐲 𝐁𝐚𝐥𝐛𝐨𝐚 once said “It ain’t about how hard you hit. 𝐈𝐭’𝐬 𝐚𝐛𝐨𝐮𝐭 𝐡𝐨𝐰 𝐡𝐚𝐫𝐝 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐠𝐞𝐭 𝐡𝐢𝐭 𝐚𝐧𝐝 𝐤𝐞𝐞𝐩 𝐦𝐨𝐯𝐢𝐧𝐠 𝐟𝐨𝐫𝐰𝐚𝐫𝐝. That is how winning is done.” * Views and ideas are my own. The content that I provide here is public and intended to be educational only and is not endorsement or financial advice. I always encourage the readers to do their research.

Last Wednesday, I had the pleasure of attending Baker McKenzie Belgium's event for their Transactional Panel on Recent Trends in Life Sciences Dealmaking and Financing. Huge thanks to Roel Meers and Julia Braun, LL.M. for your excellent moderation and thought-provoking questions. And always a pleasure to share the stage with you, Jan Van den Bossche! 💡 The public Life Sciences sector saw fewer financing deals in '24, but on average, they were larger. This tells us that investor money is still out there, but it's being allocated to fewer, lower-risk assets. Companies need strong stories, backed by solid data and great management teams, to close funding rounds. I’m often asked by European healthcare companies whether they should list in Europe or the US. As someone with an engineering and finance background I love numbers & facts. So bear in mind, there’s no one-size-fits-all answer, here are a few facts to consider: 📊 Only 4 out of 30 (13%) of European healthcare companies that listed in the US since 2018 (without an EU listing) are currently trading above their IPO price. The only notable success? BioNTech. 📊 6 out of 35 (17%) of European healthcare companies that listed in Europe (without a US listing) since 2018 are trading above their IPO price. Of course markets were different at the time & we saw a lot of early stage companies going very early to the market. Though both markets have faced similar challenges, definitely during difficult years in '22-'24, these numbers suggest that higher valuations (and fundraises) in the US don’t necessarily translate to a sustained long-term success. And that's what you're as a company are after right? For healthcare companies weighing their listing options, before deciding on a US listing, talk to us at #Euronext. We're here to support YOU and help you make the right choice for your business in the long run! #Healthcare #LifeSciences #IPO #Euronext #Dealmaking #Biotech #Fundraising #Scaling #Finance #USListing #EuropeListing

Nordic Capital’s recent pivot to sell Sunrise Medical to Platinum Equity, just after disclosing IPO plans, underscores the importance of transaction readiness in the current environment. The Wall Street Journal article linked below by Maria Armental also highlights Battery Ventures’ sale of AuditBoard to Hg following a similar pivot away from an IPO. Having a dual-track exit strategy provides the flexibility to seize the most compelling course. Amid current market uncertainties, flexibility is key. While an IPO or capital raise may maximize potential returns, an outright sale allows for a full exit and return of capital to cash-starved LPs. #Ankura Office of the CFO  #PrivateEquity  #TransactionReadiness  #MergersAndAcquisitions